Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology

finance.yahoo.com/news/biotie-tozadenant-phase-2b-parkinsons-061202657.html

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE                  8 July, 2014 at 9.10 a.m. Biotie: Tozadenant Phase 2b Parkinson` s disease study published in Lancet Neurology...

Cultural program puts art in the community's hands

www.brisbanetimes.com.au/act-news/cultural-program-puts-art-in-the-communitys-hands-20140723-zvksc.html

From dance groups for people with Parkinson' s disease to tactile art installations by the visually impaired, a new inclusive cultural program is putting the arts in the hands of...

Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States

finance.yahoo.com/news/cynapsus-therapeutics-commences-phase-2-201500570.html

Cynapsus Therapeutics Inc. , a specialty pharmaceutical company focused on Parkinson' s disease, today announced that following communication from the United States Food and Drug...

Research and Markets: Parkinson's Disease Pipeline Highlights - 2014 Update

finance.yahoo.com/news/research-markets-parkinsons-disease-pipeline-154600942.html

Research and Markets has announced the addition of the "Parkinson's Disease Pipeline Highlights - 2014 Update" report

Biotie: Tozadenant Phase 2b Parkinson's disease study published in Lancet Neurology

www.stock-world.de/nachrichten/adhoc/Biotie-Tozadenant-Phase-2b-Parkinson-s-disease-study-published-Lancet-Neurology-n5812535.html

Brisk Walking May Help Curb Parkinson's Symptoms

www.medicinenet.com/guide.asp?s=rss&k=DailyHealth&a=179315

Title: Brisk Walking May Help Curb Parkinson's Symptoms Category: Health News Created: 7/2/2014 4:35:00 PM Last Editorial Review: 7/3/2014 12:00:00 AM

Cynapsus Therapeutics Inc : Cynapsus Therapeutics Commences Phase 2 Clinical Trials in the United States

finance.yahoo.com/news/cynapsus-therapeutics-inc-cynapsus-therapeutics-201602599.html

July 17  2014 TORONTO, CANADA - Cynapsus Therapeutics Inc. (CTH: TSX-V) (CYNAF: OTCQX), a specialty pharmaceutical company focused on Parkinson` s disease, today announced that...

Brain network measures placebo effects in Parkinson's disease patients

www.news-medical.net/news/20140719/Brain-network-measures-placebo-effects-in-Parkinsons-disease-patients.aspx

Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for...

Parkinson's patients that respond favorably to sham surgery express distinct neurological profile

www.news-medical.net/news/20140721/Parkinsons-patients-that-respond-favorably-to-sham-surgery-express-distinct-neurological-profile.aspx

Parkinson's disease is the second most common neurological disorder, affecting almost 10 million people worldwide.

Proof: Parkinson's enhances creativity

www.eurekalert.org/pub_releases/2014-07/afot-ppe071414.php

( American Friends of Tel Aviv University ) Tel Aviv University has conducted the first empirical study to verify a link between Parkinson' s disease and artistic inclination. The...